Lynda Charters

Investigators have questioned the potential for the vascular density to be a biomarker for microvascular abnormalities following COVID-19 and found that longitudinal studies are needed to determine this.

Provides safe, effective injection to target choroidal, retinal tissues

Drug is prescribed as adjunctive therapy for those with glaucoma

"Tell Me Your Secrets" is the theme of the virtual April 2 event, which is expected to build on the foundation established during the first program held last fall.

Physicians offer pearls to improve visualization in eyes using retroillumination techniques

Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.

The injection of dexamethasone intraocular suspension 9% into the capsular bag may change the standard of care following cataract surgery.

Physicians find the Vivity lens offers their patients reduced glare, halos and increased spectacle independence.

Carol L. Shields, MD, and a group of colleagues conducted a retrospective case series to evaluate the likelihood of germline retinoblastoma in children with solitary unilateral retinoblastoma.

Luis Acaba-Berrocal, MD, of the Illinois Eye and Ear Infirmary in Chicago, worked with a group of colleagues to conduct a multicenter, retrospective, consecutive study of infants with ROP who had been treated with intravitreal anti-VEGF injections between 2008 and 2020 in light of the dearth of real-world data on the topic.

A team of investigators has found that the eye disease is more prevalent than first thought.

According to Claudia Perez-Straziota, MD, persistent epithelial defects do not have to live up to their name—they can be healed.

Demodex blepharitis is a virtual epidemic in the US; an estimated 20 million people have blepharitis, and of that population, almost half have Demodex. A new therapeutic is the sole treatment option that targets the disease.

Traditional thyroid eye disease therapies with their sometime limited success are making way for new drugs with the potential to provide sustained benefits for patients, according to Erin Shriver, MD.

Oculoplastic surgeons are experts at ptosis surgery. However, surgery is not for everyone, according to Andrea Kossler, MD.

Christina Y. Weng, MD, MBA, an associate professor of ophthalmology and surgical retina fellowship program director at Baylor College of Medicine in Houston, recently shared some standout therapies for macular degeneration.

The glaucoma toolbox is expanding to include laser, drug delivery systems, and minimally invasive glaucoma surgery.

This novel surgical system could dramatically improve outcomes for patients with glaucoma with its remarkable level of precision that is unachievable during standard glaucoma surgery.

Investigators conducted a study of the ocular findings in infants with congenital Zika virus syndrome that showed the findings were similar and occurred frequently among the affected infants.

Investigators at the Eye Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy, found that the appearance of the retina and optic disc was associated with the SARS-CoV-2 virus.

Study investigators compared 2 novel lens designs using data obtained from 19 investigational sites in Australia, Canada, Spain, and the UK

A pair of Japanese ophthalmologists have concluded that SARS-CoV-2 may target lacrimal gland tissue and manifest as chronic inflammation.

Tiffani Martin was diagnosed with type 1 juvenile diabetes when she was just 5 years old, and has battled myriad health issues as a result, including vision loss. Leading the charge for a multifactorial approach to combat diabetes, Kristen Nwanyanwu, MD, MBA, MHS, and her team have embraced the need for a multi-pronged program to address health disparities in diabetic retinopathy.

Utilizing new technology, surgeons can be 20 to 40 times more precise.

Proper measurement of the eye is key to predicting lens strength.

During the Glaucoma 360 New Horizons Forum at the Grand Hyatt San Francisco at Union Square, several speakers discussed the latest advances in technology.

Carel B. Hoyng, MD, noted that investigators have developed an RNA therapy to stop the progression of the disease, which ultimately leads to legal blindness.

Arshad M. Khanani, MD, MA, told attendees at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition that data from the part A of the KALAHARI trial is encouraging, showing that THR-149 has the potential to improve vision in patients with DME who have a sub-optimal response to anti-VEGF therapies.

Most patients (95%) with the PDS implanted did not need supplemental treatment before the refills, indicating the persistence and durability of the treatment.